JPMorgan initiated coverage of Protara Therapeutics (TARA) with an Overweight rating and $27 price target The company is advancing TARA-002, a lyophilized heat- and penicillin-killed preparation of strep pyogenes in non-muscle invasive bladder cancer and lymphatic malformations, the analyst tells investors in a research note. The firm believes that as the replica of approved picibanil in Japan and Taiwan, TARA-002 is “highly de-risked” based on the clinical experience picibanil has collected in the target indications.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Highlights Strong Phase 2 Data for TARA-002
- Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC
- Buy Rating on TARA-002 Supported by Comparable Efficacy and $500M Peak Sales Opportunity in Bladder Cancer
- Protara Therapeutics says TARA-002 demonstrates 68% CR rate at 6 months
- Protara Therapeutics management to meet with Oppenheimer